Through an elaborate analysis of these kallikreins, alone and in combination with other biomarkers (CA-125) and clinical parameters, they have succeeded in developing a combined marker that is both prognostic and predictive of ovarian cancer patient response to chemotherapy. Here, KLK4 is linked to ovarian carcinoma.